# Table S3. Baseline characteristics of the validation cohort used for serum total protein–related analysis.

|  |  |  |
| --- | --- | --- |
| Characteristics | Control (N=85) | MASLD (N=330) |
| **Demographics** |  |  |
| Men, n (%) | 38 (44.7%) | 220 (66.7%) |
| Age (years) | 56 (47, 62) | 43 (32, 53) |
| **Concomitant diseases** |  |  |
| Diabetes, n (%) | 12 (14.1%) | 72 (21.8%) |
| Hypertension, n (%) | 16 (18.8%) | 70 (21.2%) |
| **Body measurements** |  |  |
| BMI, kg/m2 | 22.8 (21.28, 24.28) | 26.28 (24.1, 28.0) |
| **Laboratory parameters** |  |  |
| AST, (U/L)  | 21.0 (18.1, 25.4) | 34.2 (24.3, 51.9) |
| ALT, (U/L) | 15.9 (13, 24) | 46.3 (27.1, 84.8) |
| HbA1c, % | 6.03±1.82 | 6.03±1.25 |
| Total protein, g/L | 67.4 (62.7, 72.4) | 76.2 (70.9, 80.0) |
| Albumin, g/L | 42.71±4.69 | 45.72±4.72 |
| Total cholesterol, mmol/L)  | 4.88±1.26 | 5.11±1.20 |
| HDL, mmol/L | 1.24±0.30 | 1.04±0.23 |
| LDL, mmol/L | 2.97±0.86 | 3.04±0.93 |
| TG, mmol/L | 1.23 (0.91, 1.94) | 1.96 (1.36, 2.91) |
| Platelet, ×109/L | 210.25±61.96 | 241.40±58.37 |
| Creatinine, µmol/L | 64.18±10.62 | 66.86±13.53 |

Abbreviations: MASLD, Metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; HDL, high density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride.